Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

132 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus.
Lee AB, Godfrey T, Rowley KG, Karschimkus CS, Dragicevic G, Romas E, Clemens L, Wilson AM, Nikpour M, Prior DL, Best JD, Jenkins AJ. Lee AB, et al. Intern Med J. 2006 Apr;36(4):237-43. doi: 10.1111/j.1445-5994.2006.01044.x. Intern Med J. 2006. PMID: 16640741
Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.
Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M. Golder V, et al. Semin Arthritis Rheum. 2017 Jun;46(6):798-803. doi: 10.1016/j.semarthrit.2017.01.007. Epub 2017 Jan 18. Semin Arthritis Rheum. 2017. PMID: 28216192
Thioflavin T fluorescence in human serum: correlations with vascular health and cardiovascular risk factors.
Griffin MD, Wilson LM, Mok YF, Januszewski AS, Wilson AM, Karschimkus CS, Romas E, Lee AB, Godfrey T, Wong M, Clemens L, Jenkins AJ, Howlett GJ. Griffin MD, et al. Clin Biochem. 2010 Feb;43(3):278-86. doi: 10.1016/j.clinbiochem.2009.10.010. Epub 2009 Oct 24. Clin Biochem. 2010. PMID: 19857478
A common property of amyloid-like structures is their ability to induce thioflavin T (ThT) fluorescence. We measured ThT fluorescence in serum and related these levels to traditional cardiovascular risk factors and non-invasive measures of vascular dysfunction (elasticity) …
A common property of amyloid-like structures is their ability to induce thioflavin T (ThT) fluorescence. We measured ThT fluorescence …
Presence of HIV infection in patients diagnosed with systemic lupus erythematosus.
Clutterbuck DJ, Watson J, De Ruiter A, Godfrey T, Bradbeer C. Clutterbuck DJ, et al. Rheumatology (Oxford). 2000 Sep;39(9):1047-8. doi: 10.1093/rheumatology/39.9.1047-a. Rheumatology (Oxford). 2000. PMID: 10986318 No abstract available.
Therapeutic advances in systemic lupus erythematosus.
Godfrey T, Khamashta MA, Hughes GR. Godfrey T, et al. Curr Opin Rheumatol. 1998 Sep;10(5):435-41. doi: 10.1097/00002281-199809000-00007. Curr Opin Rheumatol. 1998. PMID: 9746859 Review.
Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients.
Godfrey T, Cuadrado MJ, Fofi C, Abbs I, Khamashta MA, Nunan T, Hughes GR. Godfrey T, et al. Rheumatology (Oxford). 2001 Mar;40(3):324-8. doi: 10.1093/rheumatology/40.3.324. Rheumatology (Oxford). 2001. PMID: 11285381
Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.
Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Cuadrado MJ, et al. Medicine (Baltimore). 2000 Jan;79(1):57-68. doi: 10.1097/00005792-200001000-00006. Medicine (Baltimore). 2000. PMID: 10670410 Review.
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
Oon S, Huq M, Godfrey T, Nikpour M. Oon S, et al. Semin Arthritis Rheum. 2018 Oct;48(2):221-239. doi: 10.1016/j.semarthrit.2018.01.001. Epub 2018 Jan 6. Semin Arthritis Rheum. 2018. PMID: 29426575
Systemic lupus erythematosus: current management.
Godfrey TR, Ryan PF. Godfrey TR, et al. Med J Aust. 2001 Aug 6;175(3):125-6. Med J Aust. 2001. PMID: 11548075 No abstract available.
132 results
Jump to page